Table 2.
Outcomes by regimen type for people living with HIV who were previously treatment-naive and those who were treatment-experienced
| Characteristic | Treatment-Naive Patients (N = 1280) |
Treatment-Experienced Patients (N = 3897) |
||||||
|---|---|---|---|---|---|---|---|---|
| Dolutegravir- baseda (N=426) |
Other INSTI- basedb (N=773) |
Darunavir- based (N=81) |
P value across regimens |
Dolutegravir- based (N=2054) |
Other INSTI- based (N=1486) |
Darunavir- based (N=357) |
P value across regimens |
|
| Duration of follow-up, mean (SD), days | 342 (283) | 494 (353) | 564 (422) | <0.001 | 367 (286) | 430 (336) | 436 (341) | <0.001 |
| Remained on regimen, N (%) | 316 (74) | 601 (78) | 64 (79) | 0.3 | 1526 (74) | 1018 (69) | 212 (59) | <0.001 |
| Experienced virologic failure, (≥400 copies/mL) N (%) |
28 (7) | 93 (12) | 23 (28) | <0.001 | 115 (6) | 152 (10) | 75 (21) | <0.001 |
| Died, N (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Discontinued regimen, N (%) | 44 (10) | 79 (10) | 4 (5) | 0.3 | 226 (11) | 192 (13) | 66 (18) | <0.001 |
| Switched regimen (all changes), N (%) | 66 (15) | 93 (12) | 13 (16) | 0.2 | 302 (15) | 276 (19) | 79 (22) | <0.001 |
| Switched from regimen (but remained in category), N (%) | 21 (32) | 1 (1) | 0 (0) | <0.001 | 55 (18) | 15 (5) | 0 (0) | <0.001 |
| Switched regimen (switch resulted in new category), N (%) | 45 (68) | 92 (99) | 13 (100) | <0.001 | 247 (82) | 261 (95) | 79 (100) | <0.001 |
INSTI = integrase strand transfer inhibitor; SD = standard deviation.
a
This includes dolutegravir/abacavir/emtricitabine and dolutegravir/tenofovir/emtricitabine
b
This includes elvitegravir/cobicistat/tenofovir/emtricitabine and raltegravir/tenofovir/emtricitabine